Join Our Penny Stock Newsletter

Diadexus, Inc. - DDXSQ

RSI %R Tweets Wolf Odds
51 -95 0 17.935%

Industry: Diagnostics & Research / Sector: Healthcare

DDXSQ Chart

DDXSQ Quote

Prev Close: 0.011
Open: 0.0110
Last Trade: 0.011
Change %: 0.000%
Change: 0.0000000
Volume: 0
Avg Vol: 13788
Relative Vol: 0.00
Day Range: 0.011 -0.011
52-Week Range: 0.010 - 0.100
Market Cap: 49.2k
Float: 2.51M
Shares Outstanding: 4.1M
Insider Owned: 14.89%
Institution Owned: 25.07%
Beta: 2.83
PE Ratio: 0.00
EPS: -1.977

DDXSQ Detailed Stats

RSI:50.61 %K:4.88 Wolf Odds: 17.935% Tweets Today:0 SMA14:0.0199
stochRSI:0.68 %D:20.33 Wolf Trend:0.07 Tweet Avg:0 Pivot Price:0.0110000
%R:-95.12 %B:0.28 Wolf 3-Day:0.05 Avg. Change 3-Day:-21.110% Resistance 1:0.0110000
MFI:96.13 Bandwidth:2.007168 Wolf 7-Day:0.02 Avg. Change 7-Day:-9.047% Resistance 2:0.0110000
WolfPeak:0.59 Vortex Indicator:0.01 Wolf 14-Day:0.04 Avg. Change 14-Day:+20.69% Support 1:0.0110000
ROC 7/14:-63.3333/10.0000 Aroon Oscillator:7.1429 EOM:0.000000 Relative Vol:0.00 Support 2:0.0110000
RSI Alert:None WolfPeak Alert:None Vortex Alert:Potential Bear Aroon Alert:None EOM Alert:None

Featured News *

DDXSQ News

    DDXSQ Description

    Diadexus, Inc., a diagnostics company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company?s PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure. The company markets its products to various national and regional clinical reference laboratories and hospitals in the United States, Europe, and internationally. The company is based in Poway, California. On June 13, 2016, Diadexus, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.
    Website: http://www.diadexus.com

    DDXSQ Comments

    Recent DDXSQ Tweets

    Powered by Ekonomys ver. 9

    StockWolf is dedicated to Penny Stock quotes and data to provide information, news, and education on penny stocks to help in your due diligence.

    30min+ delay on data. All data is picked with automated algorithms and not vetted for accuracy. Please, read ALL information and disclaimers before using our service. StockWolf is not a licensed financial adviser, and not liable for your loses. Trade responsibly. This site is for education purposes only not a recommendation to buy/sell

    Information

    Stock Wolf Twitter

    Stock Wolf Facebook